Product Description

Cronyxin is indicated for use in horses for the treatment of acute inflammatory musculoskeletal conditions. The apple-flavoured paste is supplied in a convenient multi-dose 33 g dial-a-dose syringe calibrated in 100 kg bodyweight increments, allowing flexible dosing for horses of varying sizes. One syringe provides sufficient product to treat 1,500 kg bodyweight — equivalent to a three-day treatment course for a 500 kg horse. The cause of the underlying inflammatory condition should always be determined and treated with appropriate concomitant therapy, as the product may provide temporary relief that masks the appearance of effective treatment.

For Horses:

Treatment of acute inflammatory musculoskeletal disorders, including conditions where anti-inflammatory, analgesic and anti-pyretic effects are required

Anti-endotoxic activity may be relevant in cases where endotoxaemia or septic shock is present (noting specific contraindication guidance for dehydrated/hypovolaemic animals)

Which Animals Can Use Cronyxin 50 mg/g Oral Paste?

Cronyxin is licensed for use in horses only. It must not be used in pregnant mares, as reproductive safety studies have not been conducted. It must not be used in animals producing milk for human consumption. Use in foals under 6 weeks of age or in aged animals carries additional risk and requires careful veterinary assessment. Always use only under the direction of your vet.

Available Strengths & Sizes

Please order the exact pack size as specified on your veterinary prescription.

Note: Not all pack sizes may be marketed. Each 33 g syringe delivers 1,650 mg of flunixin, sufficient to treat 1,500 kg bodyweight (three days' treatment for a 500 kg horse).

Directions for Use

This is a prescription medication and must be used exactly as directed by your veterinary surgeon. Dosage is based on the horse's bodyweight, administered once daily for a maximum of 5 days according to clinical response. Ensure the horse's mouth contains no feed before administration. Refer to the dispensing label and package leaflet for full administration instructions, including correct syringe technique.

Contraindications

Source: SPC Section 4.3

Do not exceed the stated dose or duration of treatment

Do not administer concurrently with other NSAIDs or glucocorticosteroids, or within 24 hours of each other

Do not use in animals suffering from cardiac (heart) disease

Do not use in animals suffering from hepatic (liver) disease

Do not use in animals suffering from renal (kidney) disease

Do not use in animals suspected of having gastrointestinal ulceration or bleeding

Do not use in cases of known hypersensitivity to the active substance flunixin or to any of the excipients (colloidal anhydrous silica, propylene glycol, titanium dioxide E171, xanthan gum, aluminium magnesium silicate, sorbitol, apple flavour, purified water)

Do not use in dehydrated or hypovolaemic animals, except in the case of endotoxaemia or septic shock, as there is a potential risk of increased renal toxicity

Do not use in animals suffering from chronic musculoskeletal disorders

Do not use in pregnant mares — reproductive studies have not been conducted in horses

Storage & Handling

This veterinary medicinal product does not require any special storage conditions. Shelf life of the product as packaged for sale is 2 years. Shelf life after first opening the immediate packaging is 3 months. Keep out of reach of children and animals at all times — store in a closed cabinet (see human safety warnings below). Do not mix with any other veterinary medicinal product. Dispose of unused product or waste materials in accordance with local requirements.

Withdrawal periods:

Meat and offal: 15 days

Not authorised for use in animals producing milk for human consumption

Important Warnings

Source: SPC Sections 4.4 & 4.5

Animal precautions:

Use of this product may lead to temporary relief of inflammatory signs that may appear as effective treatment of the underlying disease — the cause must always be determined and treated with appropriate concomitant therapy

Animals should be rested and given a sufficient supply of drinking water throughout the course of treatment

Use in animals under 6 weeks of age or in aged animals may involve additional risk; if such use cannot be avoided, careful clinical management is required

Flunixin is toxic to avian scavengers — do not administer to animals susceptible to entering the wild fauna food chain; in the event of the death or sacrifice of treated animals, ensure carcasses are not made available to wild birds or fauna

In case of overdose, signs of gastrointestinal toxicity and other adverse reactions may occur; discontinue immediately and treat symptomatically

Human safety warnings:

This product may cause serious adverse effects if ingested, particularly by children — store in a closed cabinet, out of reach of children at all times

This product may cause hypersensitivity (allergic) reactions — avoid skin contact; wear gloves during application

Persons with known hypersensitivity to NSAIDs must not handle this product

In the event of accidental skin contact, wash the exposed area immediately with plenty of water and soap

Hypersensitivity reactions may be serious: if symptoms such as a skin rash develop, seek medical advice and show the physician this warning; swelling of the face, lips or eyes, or difficulty breathing, are serious symptoms requiring urgent medical attention

This product can cause eye irritation — avoid contact with the eyes; if the product comes into contact with the eyes, rinse immediately with plenty of water and seek medical advice

Drug interactions:

Concurrent administration of potentially nephrotoxic drugs — particularly aminoglycosides — should be avoided

Prior or concurrent administration of steroidal or other non-steroidal anti-inflammatory drugs is not recommended, as they may enhance adverse reactions

Do not use concurrently with the inhalation anaesthetic methoxyflurane, due to the risk of nephrotoxicity

Some NSAIDs are highly protein-bound and may compete with other highly protein-bound drugs, leading to increased pharmacologically active concentrations and potential toxicity

Flunixin may reduce the efficacy of certain anti-hypertensive medicines, including diuretics, ACE inhibitors, and beta blockers, through inhibition of prostaglandin synthesis

POM-V Prescription Notice

This product is a Prescription Only Medicine — Veterinary (POM-V). It may only be supplied by a veterinary surgeon or, when prescribed by a veterinary surgeon, by a pharmacist or SQP. A valid veterinary prescription is required before this product can be dispensed.

MA Number: Vm 50146/5004 (Source: VMD Product Information Database, GB territory — MA holder: Bimeda Animal Health Limited)